References
- Henriksson K G, Masi AT. Fibromyalgia and Myofascial Pain Syndromes. Bailliere's Clin Rheumat 1994; 8(4)703–19
- Granges G, Littlejohn G O. A comparative study of clinical signs in fibromyalgia/Fibrositis syndrome healthy and exercising subjects. J Rheumatol 1993; 20: 344–51
- Kosec E, Hansson P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain 1996, (in press)
- Sorensen J, Bengtsson A, Backman E, Henriksson K G, Bengtsson M. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol 1995; 24: 360–5
- Littlejohn G O, Weinstein C, Helme R D. Increased neurogenic inflammation in fibrositis syndrome. J Rheumatol 1987; 14: 1022–5
- Reilly P A, Littlejohn G O. Fibrositis/fibromyalgia syndrome: the key to the puzzle of chronic pain. Med J Aust 1990; 152: 226–8
- Caro X J. Immunofluorescent detection of IgG at the dermal-epidermal junction in patients with apparent primary fibrositis syndrome. Arthritis Rheum 1984; 27: 1174–8
- Caro X J, Wolfe F, Johnston W H, Smith A L. A controlled and blinded study of immunoreactant deposition at the dermal-epidermal junction of patients with primary fibrositis syndrome. J Rheumatol 1986; 13: 1086–92
- Enestrom S, Bengtsson A, Lindstrom F, Johan K. Attachment of IgG to dermal extracellular matrix in patients with fibromyalgia. Clin Exp Rheumatol 1990; 8: 127–35
- Wolfe F, Smythe H A, Yunus M B, Bennett R M, Bombardier C, Goldenberg D L. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160–72
- Arnett F C, Edworthy S M, Bloch D A, McShane, Fries J F, Cooper N S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–25
- Bengtsson A, Ernerudh J, Vrethem M, Skogh T. Absence of autoantibodies in primary fibromyalgia. J Rheumatol 1990; 17: 1682–3
- Wallace D J, Peter J B, Bowman R L, Wormsley S B, Silverman S. Fibromyalgia, cytokines, fatigue syndromes, and immune regulation. Advances in Pain Research and Therapy, J R Fricton, E Awad. Raven Press Ltd., New York 1990; 17: 277–87
- Værøy H, Helle R, Forre O, Kåss E, Terenius L. Elevated CSF levels of substance P and high incidence Raynaud phenomenon in patients with fibromyalgia: new features of diagnosis. Pain 1988; 32: 21–6
- Foreman J C, Jordan C C, Oehme P, Renner H. Structure-activity relationships for some substance P-related peptides that cause wheal and flare reactions in human skin. J Physiol 1983; 335: 449–65
- Rosen N B, Masi AT. Physical medicine and rehabilitation approaches to the management of myofascial pain and fibromyalgia syndrome. Fibromyalgia and Myofascial Pain Syndromes. Baillière's. Clin Rheumat 1994; 8(4)881–916
- Skotfitsch G, Savitt J M, Jacobowitz D M. Suggestive evidence for a functional unit between mast cells and substance P fibers in the rat diaphragm and mesentery. Histochemistry 1985; 82: 5–8
- Urmacher C. Normal skin. Histology for Pathologists, SS Sternberger. Raven Press, Ltd., New York 1992; 392